Developer docs
API playgroundTry for free, no card

Search company profiles

Foghorn Therapeutics

Full company profile

uuid000075b

Namestring
Foghorn Therapeutics
Legal namestring
Foghorn Therapeutics, Inc.
Websiteurl
foghorntx.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Foghorn Therapeutics is a clinical-stage biotechnology company founded in 2015 and headquartered in Watertown, Massachusetts, that is developing a new class of precision oncology therapeutics designed to correct abnormal gene expression by targeting the chromatin regulatory system — the cellular machinery that controls which genes are turned on or off through remodeling of DNA's 3D structure. Its proprietary platform, called Gene Traffic Control, is described by the company as the only system capable of studying and targeting the chromatin regulatory system at scale, in context, and in an integrated way, and underpins a pipeline of enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. The lead program is FHD-909 (LY4050784), a potent, first-in-class, allosteric, orally available selective SMARCA2 inhibitor in Phase 1 development for SMARCA4-mutant cancers including non-small cell lung cancer; the broader pipeline includes FHD-286 (camibirstat, a dual SMARCA4/SMARCA2 inhibitor for myeloid malignancies), FHD-609 (a BRD9 degrader for synovial sarcoma), and selective degrader programs against CBP, EP300, and ARID1B for various solid and hematologic tumors.

The business model is a hybrid of clinical-stage biopharma R&D plus partnership monetization. Foghorn has no approved products for commercial sale and generates no product pricing revenue; its entire FY2025 revenue of $30.91 million is collaboration revenue, effectively sourced from a single counterparty — Eli Lilly (Loxo Oncology at Lilly) — under a 2023 co-development and co-commercialization agreement covering FHD-909, an undisclosed oncology target, and three discovery programs, with a 50/50 U.S. economic split and ex-U.S. royalties on the Lilly-partnered assets. The company serves two distinct customer sets: enterprise partners (Eli Lilly being the only material one) and, at clinical-trial stage, oncologists and patients with genetically defined cancers (SMARCA4-mutant, ARID1A-mutant, CBP/EP300-mutant, and related chromatin-driven tumors). Go-to-market occurs through scientific conference presence (AACR, ASH, ESMO), investor relations, and clinical-trial enrollment on ClinicalTrials.gov, rather than traditional sales channels. Recent capital actions include a $110 million registered direct offering in May 2024 and a $50 million equity financing in January 2026 at a 30% premium, bringing pro forma cash to ~$208.9 million and extending runway into the first half of 2028.

Short descriptiontext

Foghorn Therapeutics is a clinical-stage biotechnology company developing precision oncology therapeutics that target the chromatin regulatory system via its proprietary Gene Traffic Control platform, with lead assets including FHD-909 (selective SMARCA2 inhibitor) partnered with Eli Lilly.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, chromatin regulatory system, targeted protein degradation, small molecule drug discovery, cancer therapeutics pipeline
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Precision Oncology Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration Revenue
TypeLicensing Royalties
Description

Revenue from collaboration agreements, primarily with Eli Lilly (Loxo Oncology at Lilly) for co-development of SMARCA2 inhibitor program and discovery programs. Includes potential milestone payments and royalties.

minichart.com.sg
2Research and Development
TypeSubscription Recurring
Description

Clinical-stage biotechnology company with no approved products for commercial sale. Relies on collaboration revenues and financing to fund operations.

minichart.com.sg
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Foghorn Therapeutics is a clinical-stage biotechnology company developing precision oncology therapeutics that target the chromatin regulatory system using its proprietary Gene Traffic Control platform. Its pipeline includes first-in-class enzymatic inhibitors (FHD-909, FHD-286), targeted protein degraders (FHD-609, selective CBP, EP300, and ARID1B degraders), and partnered discovery programs, with its lead SMARCA2 inhibitor program co-developed with Eli Lilly. The company has no approved commercial products and generates revenue primarily from collaboration agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Complete and durable tumor regression in syngeneic mouse models treated with FHD-909 (SMARCA2 inhibitor) and anti-PD-1 therapy, with responses maintained for at least 70 days post-treatment
+1 more record
Product overview1 text field

Foghorn Therapeutics is a clinical-stage biotechnology company pioneering a new class of precision therapeutic candidates that treat serious diseases by correcting abnormal gene expression through modulation of the chromatin regulatory system. The company's proprietary Gene Traffic Control platform enables the development of enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. The core product portfolio includes: FHD-909 (LY4050784), a selective SMARCA2 inhibitor partnered with Eli Lilly for SMARCA4-mutant cancers in Phase 1; FHD-286, a dual SMARCA4/SMARCA2 inhibitor for myeloid malignancies; FHD-609, a BRD9 degrader for synovial sarcoma; and multiple selective degrader programs targeting CBP, EP300, and ARID1B for various cancers, all in preclinical or IND-enabling stages. Three additional discovery programs and one undisclosed partnered program round out the pipeline.

Product and service1 record
1FHD-909 (LY4050784) - Selective SMARCA2 Inhibitor
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Collaboration agreement for further clinical development of FHD-286 (camibirstat) in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Yatiri Bio's AI-driven ProteoCharts platform achieved 100% concordance in predicting treatment response. Includes clinical and sales milestones valued at over $40 million.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development and co-commercialization agreement on selective SMARCA2 oncology program (FHD-909, a selective inhibitor and a selective degrader) with 50/50 U.S. economic split and ex-U.S. royalties. Also includes one additional undisclosed oncology target and three discovery programs using Foghorn's Gene Traffic Control platform.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

C4 Therapeutics is a clinical-stage biotech developing targeted protein degraders in oncology, including programs against cancer-driving targets such as BRD9 (same target class as Foghorn's FHD-609) and IKZF1/3. Direct overlap in protein degradation chemistry, chromatin/epigenetic targets, and oncology indications.

TypeDirect peer
Description

Tango Therapeutics applies synthetic lethality and cancer genetics to develop precision oncology therapeutics, with a pipeline targeting DNA damage response and chromatin-related dependencies. Direct peer in precision oncology discovery with similar scientific premise of exploiting tumor-specific genetic vulnerabilities.

TypeDirect peer
Description

Repare Therapeutics is a precision oncology company developing synthetic lethality-based therapies, with programs targeting DNA damage response and genome instability. Directly comparable business model of identifying genetically defined cancer patient populations and developing selective therapies against tumor dependencies.

4Syros Pharmaceuticals
TypeDirect peer
Description

Syros Pharmaceuticals develops gene control medicines targeting the transcriptional regulation of disease-driving genes, including programs against CDK7 and mutant super-enhancers in cancer. Direct peer in chromatin/transcription regulation-based precision oncology, with platform-level similarity to Foghorn's Gene Traffic Control approach.

TypeDirect peer
Description

Kymera Therapeutics is a clinical-stage biotech developing targeted protein degraders (Pegasus platform) with oncology and immunology programs. Directly comparable in protein degrader chemistry and target selection rationale, competing for talent, partnerships, and capital in the same therapeutic modality space.

TypeBroad incumbent
Description

Arvinas is a clinical-stage leader in targeted protein degradation (PROTAC platform) with late-stage programs in oncology. Comparable technology platform (heterobifunctional degraders) and similar oncology focus, though Arvinas is more advanced commercially and partnered with Pfizer, giving it incumbent scale advantages over Foghorn.

7Nuvalent
TypeDirect peer
Description

Nuvalent is a clinical-stage precision oncology company developing selective kinase inhibitors designed to address resistance and selectivity limitations of existing targeted therapies. Directly comparable as a publicly traded clinical-stage precision oncology biotech with similar scientific ethos of rational drug design and similar company-size/scale profile.

TypeBroad incumbent
Description

Constellation Pharmaceuticals developed selective inhibitors of chromatin regulators (EZH2, CBP/p300) for cancer prior to its $1.7B acquisition by MorphoSys in 2021. Highly comparable in chromatin regulatory system targeting, though no longer independent—useful as a historical valuation/pipeline benchmark for Foghorn.

TypeEmerging player
Description

Schrödinger operates a physics-based computational platform for drug discovery, with its own pipeline of precision oncology candidates and a substantial software/services business. Comparable as a publicly traded platform-based drug discovery company, though its computational focus differs from Foghorn's chromatin biology approach.

TypeDirect peer
Description

Arcus Biosciences is a clinical-stage oncology company developing immuno-oncology and cancer cell-intrinsic therapies, partnered with Gilead. Comparable scale and clinical stage, with overlap in oncology patient populations and partnership-driven commercialization model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Foghorn Therapeutics

Precision Oncology Therapeuticsfoghorntx.com

Foghorn Therapeutics is a clinical-stage biotechnology company developing precision oncology therapeutics that target the chromatin regulatory system via its proprietary Gene Traffic Control platform, with lead assets including FHD-909 (selective SMARCA2 inhibitor) partnered with Eli Lilly.

What Foghorn Therapeutics does

Foghorn Therapeutics is a clinical-stage biotechnology company founded in 2015 and headquartered in Watertown, Massachusetts, that is developing a new class of precision oncology therapeutics designed to correct abnormal gene expression by targeting the chromatin regulatory system — the cellular machinery that controls which genes are turned on or off through remodeling of DNA's 3D structure. Its proprietary platform, called Gene Traffic Control, is described by the company as the only system capable of studying and targeting the chromatin regulatory system at scale, in context, and in an integrated way, and underpins a pipeline of enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. The lead program is FHD-909 (LY4050784), a potent, first-in-class, allosteric, orally available selective SMARCA2 inhibitor in Phase 1 development for SMARCA4-mutant cancers including non-small cell lung cancer; the broader pipeline includes FHD-286 (camibirstat, a dual SMARCA4/SMARCA2 inhibitor for myeloid malignancies), FHD-609 (a BRD9 degrader for synovial sarcoma), and selective degrader programs against CBP, EP300, and ARID1B for various solid and hematologic tumors.

The business model is a hybrid of clinical-stage biopharma R&D plus partnership monetization. Foghorn has no approved products for commercial sale and generates no product pricing revenue; its entire FY2025 revenue of $30.91 million is collaboration revenue, effectively sourced from a single counterparty — Eli Lilly (Loxo Oncology at Lilly) — under a 2023 co-development and co-commercialization agreement covering FHD-909, an undisclosed oncology target, and three discovery programs, with a 50/50 U.S. economic split and ex-U.S. royalties on the Lilly-partnered assets. The company serves two distinct customer sets: enterprise partners (Eli Lilly being the only material one) and, at clinical-trial stage, oncologists and patients with genetically defined cancers (SMARCA4-mutant, ARID1A-mutant, CBP/EP300-mutant, and related chromatin-driven tumors). Go-to-market occurs through scientific conference presence (AACR, ASH, ESMO), investor relations, and clinical-trial enrollment on ClinicalTrials.gov, rather than traditional sales channels. Recent capital actions include a $110 million registered direct offering in May 2024 and a $50 million equity financing in January 2026 at a 30% premium, bringing pro forma cash to ~$208.9 million and extending runway into the first half of 2028.

Foghorn Therapeutics firmographics

Firmographics
Name
Foghorn Therapeutics
Legal name
Foghorn Therapeutics, Inc.
Website
https://foghorntx.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Foghorn Therapeutics is a clinical-stage biotechnology company developing precision oncology therapeutics that target the chromatin regulatory system via its proprietary Gene Traffic Control platform, with lead assets including FHD-909 (selective SMARCA2 inhibitor) partnered with Eli Lilly.
Ownership category
akta.pro rank

Foghorn Therapeutics industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision oncology therapeutics
  • Chromatin regulatory system
  • Targeted protein degradation
  • Small molecule drug discovery
  • Cancer therapeutics pipeline

Where Foghorn Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Foghorn Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Collaboration Revenue: Revenue from collaboration agreements, primarily with Eli Lilly (Loxo Oncology at Lilly) for co-development of SMARCA2 inhibitor program and discovery programs. Includes potential milestone payments and royalties.
  2. Research and Development: Clinical-stage biotechnology company with no approved products for commercial sale. Relies on collaboration revenues and financing to fund operations.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Foghorn Therapeutics product offering

Product offering

Core offering

Foghorn Therapeutics is a clinical-stage biotechnology company developing precision oncology therapeutics that target the chromatin regulatory system using its proprietary Gene Traffic Control platform. Its pipeline includes first-in-class enzymatic inhibitors (FHD-909, FHD-286), targeted protein degraders (FHD-609, selective CBP, EP300, and ARID1B degraders), and partnered discovery programs, with its lead SMARCA2 inhibitor program co-developed with Eli Lilly. The company has no approved commercial products and generates revenue primarily from collaboration agreements.

Product overview

Foghorn Therapeutics is a clinical-stage biotechnology company pioneering a new class of precision therapeutic candidates that treat serious diseases by correcting abnormal gene expression through modulation of the chromatin regulatory system. The company's proprietary Gene Traffic Control platform enables the development of enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. The core product portfolio includes: FHD-909 (LY4050784), a selective SMARCA2 inhibitor partnered with Eli Lilly for SMARCA4-mutant cancers in Phase 1; FHD-286, a dual SMARCA4/SMARCA2 inhibitor for myeloid malignancies; FHD-609, a BRD9 degrader for synovial sarcoma; and multiple selective degrader programs targeting CBP, EP300, and ARID1B for various cancers, all in preclinical or IND-enabling stages. Three additional discovery programs and one undisclosed partnered program round out the pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • FHD-909 (LY4050784) - Selective SMARCA2 Inhibitor

Quantifiable outcome

  • Complete and durable tumor regression in syngeneic mouse models treated with FHD-909 (SMARCA2 inhibitor) and anti-PD-1 therapy, with responses maintained for at least 70 days post-treatment
  • +1 more outcomes

Companies that use Foghorn Therapeutics

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles3 records

Foghorn Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Foghorn Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered major and core.

  • Yatiri BiomajorStrategic or Co-development Partner · 10 February 2026Collaboration agreement for further clinical development of FHD-286 (camibirstat) in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Yatiri Bio's AI-driven ProteoCharts platform achieved 100% concordance in predicting treatment response. Includes clinical and sales milestones valued at over $40 million.
  • Eli Lilly (Loxo Oncology at Lilly)coreStrategic or Co-development PartnerCo-development and co-commercialization agreement on selective SMARCA2 oncology program (FHD-909, a selective inhibitor and a selective degrader) with 50/50 U.S. economic split and ex-U.S. royalties. Also includes one additional undisclosed oncology target and three discovery programs using Foghorn's Gene Traffic Control platform.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Foghorn Therapeutics competitors and assessment

Company assessment

Direct peers

  • C4 Therapeutics: C4 Therapeutics is a clinical-stage biotech developing targeted protein degraders in oncology, including programs against cancer-driving targets such as BRD9 (same target class as Foghorn's FHD-609) and IKZF1/3. Direct overlap in protein degradation chemistry, chromatin/epigenetic targets, and oncology indications.
  • Tango Therapeutics: Tango Therapeutics applies synthetic lethality and cancer genetics to develop precision oncology therapeutics, with a pipeline targeting DNA damage response and chromatin-related dependencies. Direct peer in precision oncology discovery with similar scientific premise of exploiting tumor-specific genetic vulnerabilities.
  • Repare Therapeutics: Repare Therapeutics is a precision oncology company developing synthetic lethality-based therapies, with programs targeting DNA damage response and genome instability. Directly comparable business model of identifying genetically defined cancer patient populations and developing selective therapies against tumor dependencies.
  • Syros Pharmaceuticals: Syros Pharmaceuticals develops gene control medicines targeting the transcriptional regulation of disease-driving genes, including programs against CDK7 and mutant super-enhancers in cancer. Direct peer in chromatin/transcription regulation-based precision oncology, with platform-level similarity to Foghorn's Gene Traffic Control approach.
  • Kymera Therapeutics: Kymera Therapeutics is a clinical-stage biotech developing targeted protein degraders (Pegasus platform) with oncology and immunology programs. Directly comparable in protein degrader chemistry and target selection rationale, competing for talent, partnerships, and capital in the same therapeutic modality space.
  • Nuvalent: Nuvalent is a clinical-stage precision oncology company developing selective kinase inhibitors designed to address resistance and selectivity limitations of existing targeted therapies. Directly comparable as a publicly traded clinical-stage precision oncology biotech with similar scientific ethos of rational drug design and similar company-size/scale profile.
  • Arcus Biosciences: Arcus Biosciences is a clinical-stage oncology company developing immuno-oncology and cancer cell-intrinsic therapies, partnered with Gilead. Comparable scale and clinical stage, with overlap in oncology patient populations and partnership-driven commercialization model.

Broad incumbents

  • Arvinas: Arvinas is a clinical-stage leader in targeted protein degradation (PROTAC platform) with late-stage programs in oncology. Comparable technology platform (heterobifunctional degraders) and similar oncology focus, though Arvinas is more advanced commercially and partnered with Pfizer, giving it incumbent scale advantages over Foghorn.
  • Constellation Pharmaceuticals: Constellation Pharmaceuticals developed selective inhibitors of chromatin regulators (EZH2, CBP/p300) for cancer prior to its $1.7B acquisition by MorphoSys in 2021. Highly comparable in chromatin regulatory system targeting, though no longer independent—useful as a historical valuation/pipeline benchmark for Foghorn.

Emerging players

  • Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery, with its own pipeline of precision oncology candidates and a substantial software/services business. Comparable as a publicly traded platform-based drug discovery company, though its computational focus differs from Foghorn's chromatin biology approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Foghorn Therapeutics social profiles

Digital presence

Foghorn Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Foghorn Therapeutics leadership team

Management profile

Number of profiles

Profiles18 records

Foghorn Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Foghorn Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Foghorn Therapeutics

What does Foghorn Therapeutics do?

Foghorn Therapeutics is a clinical-stage biotechnology company developing precision oncology therapeutics that target the chromatin regulatory system using its proprietary Gene Traffic Control platform. Its pipeline includes first-in-class enzymatic inhibitors (FHD-909, FHD-286), targeted protein degraders (FHD-609, selective CBP, EP300, and ARID1B degraders), and partnered discovery programs, with its lead SMARCA2 inhibitor program co-developed with Eli Lilly. The company has no approved commercial products and generates revenue primarily from collaboration agreements.

Is Foghorn Therapeutics a public or private company?

Foghorn Therapeutics is a public company. It is classified as public and is currently operating.

When was Foghorn Therapeutics founded?

Foghorn Therapeutics was founded in 2015. It employs 101 to 250 people.

Where is Foghorn Therapeutics based?

Foghorn Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Foghorn Therapeutics make money?

Two revenue lines are on record. Collaboration Revenue is the primary driver. The others are research and Development.

Who are Foghorn Therapeutics's main competitors?

Direct peers on record are C4 Therapeutics, Tango Therapeutics, Repare Therapeutics, Syros Pharmaceuticals, Kymera Therapeutics, Nuvalent and Arcus Biosciences. Broad incumbents are Arvinas and Constellation Pharmaceuticals. Schrödinger is listed as an emerging player.

Does Foghorn Therapeutics have an API?

No public API is recorded for Foghorn Therapeutics.

What industry is Foghorn Therapeutics in?

Foghorn Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPomerantz LLP is investigating claims on behalf of Foghorn Therapeutics investors, alleging securities fraud. The investigation follows Foghorn's decision to halt its FHD-909 program and a 30.82% stock drop to $2.02. Investors are advised to contact the firm's attorney.MarketScreenerFoghorn Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Foghorn Therapeutics reported net income of $31.08 million for the nine months ended September 30, 2026, compared to a $52.62 million loss a year earlier. Basic EPS from continuing operations was $0.44 versus a $0.84 loss, and diluted EPS was $0.43 versus a $0.84 loss.YahooFoghorn Therapeutics Inc. (FHTX) Q3 Earnings and Revenues Beat EstimatesFoghorn Therapeutics reported Q3 EPS of $0.8, beating the consensus loss of $0.23, and revenue of $83.54 million, up 974% from the prior quarter. The company has surpassed consensus EPS and revenue estimates twice and three times over the last four quarters, respectively.Business & FinancialFoghorn Therapeutics Provides Third Quarter 2026 Financial And Corporate UpdateFoghorn Therapeutics reported Q3 2026 net income of $58.2 million and collaboration revenue of $83.5 million, with cash of $156.2 million. The company is advancing an oral IBD program with first-in-human trials by end of 2027 and an EP300 degrader with an IND targeted in 2027.FinancialContent Business PageFoghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate UpdateFoghorn Therapeutics reported Q3 2026 net income of $58.2 million and collaboration revenue of $83.5 million, up from $8.2 million a year earlier. The company holds $156.2 million in cash, providing runway into the second half of 2029, and is advancing its IBD and EP300 degrader programs.YahooFoghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate UpdateFoghorn Therapeutics reported Q3 2026 net income of $58.2 million and collaboration revenue of $83.5 million, up from $8.2 million a year earlier. The company holds $156.2 million in cash, providing runway into the second half of 2029, and plans first-in-human trials for its IBD program by end of 2027 and an IND for its EP300 degrader in 2027.Stock TitanFoghorn Q3 Earnings: $58.2M Net Income, $74.1M AdjustmentFoghorn Therapeutics reported Q3 2026 net income of $58.2 million, up from a $15.8 million loss in the same period. A $74.1 million catch-up adjustment drove the revenue increase, and the company has $156.2 million in cash with runway into 2029.PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPomerantz LLP is investigating claims on behalf of Foghorn Therapeutics investors over potential securities fraud. The investigation follows Foghorn's decision to halt its FHD-909 program and a 30.82% stock drop to $2.02 per share. Investors are advised to contact the firm for more information.PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPomerantz LLP is investigating claims on behalf of Foghorn Therapeutics investors over potential securities fraud. The investigation follows Foghorn's decision to halt its FHD-909 program and a 30.82% stock drop to $2.02 per share. Investors are advised to contact the firm for more information.FinancialContent Business PageINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPomerantz LLP is investigating claims on behalf of Foghorn Therapeutics investors, alleging securities fraud. The investigation follows Foghorn's decision to halt its FHD-909 program and a 30.82% stock drop to $2.02 on October 2, 2026. Investors are advised to contact the firm's attorney.